New study supports adding extra chemo drug to treat CNS lymphomas

A study published in The Lancet suggests that adding high-dose cytarabine to standard methotrexate treatment of primary central nervous system (CNS) lymphomas results in a significantly higher remission rate than methotrexate alone.

Patients

The study involved 79 adults with non-Hodgkin lymphoma confined to the central nervous system (CNS), cranial nerves, or eyes.

Researchers

This was a Phase II trial carried out by researchers at San Raffaele Scientific Institute in Milan, Italy, and led by Andres J.M. Ferreri, M.D.

Results

Complete remission rates after a median follow-up of 30 months:
- Among patients who got methotrexate plus cytarabine: 46 percent
- Among patients who got methotrexate: 19 percent

However, 92 percent of those patients who got both drugs experienced grade 3 or 4 hematological toxicity, compared to only 15 percent for the patients receiving only the methotrexate.

NB: Treatment of virtually all patients included whole-brain irradiation.

Conclusion

According to the authors, "The addition of high-dose cytarabine to high-dose methotrexate is associated with a remarkable outcome benefit in patients with primary central nervous system lymphoma. This combination could be used as an upfront approach in patients aged 75 years and younger and with adequate hepatic and renal function, with appropriate antimicrobial prophylaxis."

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap